- Home
- MBRX vs THAR Comparison
MBRX vs THAR Comparison
Compare MBRX & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- THAR
- Stock Information
- Founded
- MBRX 2015
- THAR 2017
- Country
- MBRX United States
- THAR United States
- Employees
- MBRX N/A
- THAR N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- MBRX Health Care
- THAR Health Care
- Exchange
- MBRX Nasdaq
- THAR Nasdaq
- Market Cap
- MBRX 4.4M
- THAR 4.0M
- IPO Year
- MBRX 2016
- THAR 2022
- Fundamental
- Price
- MBRX $0.81
- THAR $1.25
- Analyst Decision
- MBRX Strong Buy
- THAR Strong Buy
- Analyst Count
- MBRX 3
- THAR 1
- Target Price
- MBRX $17.33
- THAR $17.00
- AVG Volume (30 Days)
- MBRX 651.2K
- THAR 135.3K
- Earning Date
- MBRX 05-09-2025
- THAR 05-08-2025
- Dividend Yield
- MBRX N/A
- THAR N/A
- EPS Growth
- MBRX N/A
- THAR N/A
- EPS
- MBRX N/A
- THAR N/A
- Revenue
- MBRX N/A
- THAR N/A
- Revenue This Year
- MBRX N/A
- THAR N/A
- Revenue Next Year
- MBRX N/A
- THAR N/A
- P/E Ratio
- MBRX N/A
- THAR N/A
- Revenue Growth
- MBRX N/A
- THAR N/A
- 52 Week Low
- MBRX $0.40
- THAR $1.14
- 52 Week High
- MBRX $5.91
- THAR $6.99
- Technical
- Relative Strength Index (RSI)
- MBRX 33.73
- THAR 33.84
- Support Level
- MBRX $0.92
- THAR $1.20
- Resistance Level
- MBRX $1.04
- THAR $1.47
- Average True Range (ATR)
- MBRX 0.10
- THAR 0.16
- MACD
- MBRX -0.02
- THAR -0.01
- Stochastic Oscillator
- MBRX 6.22
- THAR 20.04
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.